A statement released earlier today by Barclays about Momenta Pharma (NASDAQ:MNTA) bumps the target price to $19.00
- Updated: October 11, 2016
Boasting a price of $11.77, Momenta Pharma (NASDAQ:MNTA) traded 7.27% higher on the day. The last closing price is up 14.68% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. Momenta Pharma has recorded a 50-day average of $11.92 and a two hundred day average of $11.00. Trade Volume was down over the average, with 235,387 shares of MNTA changing hands under the typical 531,912
Reporting a possible upside of 0.61%, Barclays upped the target price of Momenta Pharma (NASDAQ:MNTA) to $19.00
Recent Performance Chart
Momenta Pharma has with a one year low of $7.86 and a one year high of $18.85 and has a total market value of $0.
In addition to Barclays reporting its stock price target, a total of 9 brokers have issued a research note on the company. The average stock price target is $16.33 with 5 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 3 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Momenta Pharma (NASDAQ:MNTA)
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.